Study summary
Sonelokimab kept two thirds of people at a 75% response for a year
67.2%reached at least a 75% response at 52 weeks
What was tested
Sonelokimab, a nanobody blocking IL-17A and IL-17F, in the VELA-1 and VELA-2 phase 3 trials for moderate to severe hidradenitis suppurativa.
What they found
- At 52 weeks, 67.2% reached at least a 75% improvement and 33.1% a complete response.
- The company planned an FDA application by late September 2026.
What it means
Likely the next approved biologic. Results are company-reported and await full publication.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.